1. Discuss how patients get put on these medications and why/how they should be transitioned to more evidence based treatments.
Often we see a great deal of misinformation in the care of patients with diabetes, and often this misinformation is centered around the role and choice of medications. Many patients, especially newly diagnosed patients, are prescribed medications that do not fit into the scheme of the ADA / AACE guidelines / best evidence based practices – for instance, starting on Januvia (sitagliptin) or Rybelsus (semaglutide) as initial monotherapy without a compelling indication or reason.
In this discussion, please talk about how patients get put on these medications and why/how they should be transitioned to more evidence based treatments.
- Is it okay to start a patient on a drug (particularly an oral drug) other than metformin as an initial drug? Please cite possible circumstances where this could be reasonable.
- What anti-diabetic medications have compelling evidence for use in select populations, possibly as initial therapy?
- (eg. SGLT2Is – Patients with type 2 diabetes and a high risk of cardiovascular disease had reduced risk of a cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke relative to those randomized to receive placebo)
- What additional medications, other than those for glucose control, should be included in a comprehensive pharmacotherapeutic plan and why? [See textbook section on Treatment of Concomitant Conditions]
· Please use references no older than 5 years.
· Please questions must be answered in your own words, using first person “I” and speaking to your own experiences (past, current, and future expectations) in conjunction with course resources (textbook. Dynamed and current peer-reviewed literature).